AC Immune Initiates Final Cohort in Alzheimer's Trial, Secures $12M Takeda Milestone
ACIU has more than doubled off its 52-week low of $1.51.
Summary
AC Immune SA announced the initiation of the final cohort in its Phase 1b/2 ABATE trial for ACI-24, an Alzheimer's treatment, triggering a $12 million milestone payment from Takeda.
Key Events · Product Development and Regulatory · ACIU
-
Clinical Trial Advancement
AC Immune initiated the final Cohort AD4 in its Phase 1b/2 ABATE trial for ACI-24, an anti-Abeta active immunotherapy for Alzheimer's disease.
-
Milestone Payment Received
The initiation of Cohort AD4 triggered a $12 million milestone payment from Takeda, under their exclusive option and license agreement.
-
Future Data Readout
Data from the earlier Cohorts AD1, AD2, and AD3 after 12 months of treatment are expected in Q2 2026.
Analysis · ACIU · Life Sciences
This filing details significant progress in AC Immune's lead Alzheimer's drug candidate, ACI-24, by advancing to the final cohort of its Phase 1b/2 ABATE trial. The associated $12 million milestone payment from Takeda provides non-dilutive capital and underscores the value of their partnership. This clinical advancement, coupled with the financial inflow, is a strong positive signal for the company's development pipeline and financial runway, especially with 12-month data from earlier cohorts expected soon.
At the time of this filing, ACIU was trading at $3.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $298.2M. The 52-week trading range was $1.51 to $4.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.